Europeiska unionen - svenska - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostatiska neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - enzalutamid - filmdragerad tablett - 40 mg - laktosmonohydrat hjälpämne; enzalutamid 40 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - enzalutamid - filmdragerad tablett - 80 mg - enzalutamid 80 mg aktiv substans; laktosmonohydrat hjälpämne